Trials / Completed
CompletedNCT04189705
A Study to Evaluate the Efficacy and Safety of MCT-SR in Patients With Gastritis
A Multi-center, Randomized, Double-blind, Active-controlled, Non-inferiority, Phase 3 Study to Evaluate the Efficacy and Safety of MCT-SR in Patients With Gastritis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 392 (actual)
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 19 Years – 74 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, randomized, double-blind, active-controlled, non-inferiority, phase 3 study to evaluate the efficacy and safety of MCT-SR in patients with gastritis.
Detailed description
To contribute greater treatment compliance and patient convenience, the rebamipide SR formulation has been developed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MCT-SR | Rebamipide 150mg |
| DRUG | Mucosta Tab. | Rebamipide 100mg |
Timeline
- Start date
- 2019-12-30
- Primary completion
- 2020-04-23
- Completion
- 2020-04-23
- First posted
- 2019-12-06
- Last updated
- 2021-03-11
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04189705. Inclusion in this directory is not an endorsement.